Category: Psychedelic Bulletin - Page 12 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by 1m Shares; 6 Projects Readers are Working On

Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by 1m Shares; 6 Projects Readers are Working On

Post published:April 8, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1, 2022)

Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1, 2022)

Post published:April 1, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing Footage Emerges from MAPS Trial

Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing Footage Emerges from MAPS Trial

Post published:March 25, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine?

Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine?

Post published:March 18, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Tensions Rise Among Oregon’s Psilocybin Advisory Board; Colleges Team up to Develop Psychedelic Curriculum

Psychedelic Bulletin: Tensions Rise Among Oregon’s Psilocybin Advisory Board; Colleges Team up to Develop Psychedelic Curriculum

Post published:March 11, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead for Psychedelic Medicine

Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead for Psychedelic Medicine

Post published:March 7, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?

Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?

Post published:February 28, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in Depression; Cybin Partners with Chopra Foundation

Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in Depression; Cybin Partners with Chopra Foundation

Post published:February 18, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Mindstate Design Labs Leaves Stealth Mode; No Synthetic Psilocybin in Oregon?

Psychedelic Bulletin: Mindstate Design Labs Leaves Stealth Mode; No Synthetic Psilocybin in Oregon?

Post published:February 14, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Patent Granted Covering DMT Vapes; Microdosing Produces “Negligible” Effects

Psychedelic Bulletin: Patent Granted Covering DMT Vapes; Microdosing Produces “Negligible” Effects

Post published:February 6, 2022
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.